Concepts (218)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colorectal Neoplasms | 21 | 2025 | 576 | 5.720 |
Why?
|
| Early Detection of Cancer | 10 | 2022 | 362 | 2.200 |
Why?
|
| Occult Blood | 8 | 2022 | 31 | 1.990 |
Why?
|
| Colonoscopy | 9 | 2022 | 238 | 1.860 |
Why?
|
| Colonic Neoplasms | 6 | 2024 | 248 | 1.370 |
Why?
|
| Adenoma | 3 | 2022 | 128 | 1.220 |
Why?
|
| Systemic Inflammatory Response Syndrome | 4 | 2025 | 173 | 1.040 |
Why?
|
| Lymphocytes | 3 | 2023 | 408 | 0.960 |
Why?
|
| Mass Screening | 7 | 2022 | 785 | 0.870 |
Why?
|
| Colonic Polyps | 2 | 2021 | 78 | 0.790 |
Why?
|
| Adenomatous Polyps | 1 | 2021 | 13 | 0.730 |
Why?
|
| Polyps | 1 | 2021 | 44 | 0.700 |
Why?
|
| Neoplasm Staging | 8 | 2024 | 1275 | 0.670 |
Why?
|
| Anemia | 2 | 2023 | 341 | 0.620 |
Why?
|
| Guaiac | 1 | 2017 | 1 | 0.560 |
Why?
|
| Xylenes | 4 | 2007 | 13 | 0.540 |
Why?
|
| Prognosis | 9 | 2023 | 4686 | 0.530 |
Why?
|
| Inflammation | 3 | 2024 | 1445 | 0.530 |
Why?
|
| Body Composition | 3 | 2024 | 521 | 0.510 |
Why?
|
| Anti-Infective Agents, Local | 5 | 2007 | 71 | 0.490 |
Why?
|
| Sigmoidoscopy | 1 | 2013 | 9 | 0.440 |
Why?
|
| Leukocyte L1 Antigen Complex | 2 | 2022 | 15 | 0.380 |
Why?
|
| Diabetes Complications | 1 | 2013 | 203 | 0.380 |
Why?
|
| Aspirin | 1 | 2013 | 222 | 0.370 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2013 | 223 | 0.370 |
Why?
|
| Neutrophils | 3 | 2023 | 381 | 0.370 |
Why?
|
| Aged | 14 | 2025 | 19727 | 0.360 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 304 | 0.360 |
Why?
|
| Trypsin | 1 | 2010 | 96 | 0.350 |
Why?
|
| Microbiological Techniques | 1 | 2010 | 31 | 0.350 |
Why?
|
| Humans | 38 | 2025 | 125358 | 0.350 |
Why?
|
| Robotic Surgical Procedures | 2 | 2025 | 207 | 0.340 |
Why?
|
| C-Reactive Protein | 3 | 2025 | 433 | 0.330 |
Why?
|
| Catheters | 1 | 2010 | 86 | 0.330 |
Why?
|
| Anti-Bacterial Agents | 6 | 2011 | 2430 | 0.330 |
Why?
|
| Drug Utilization | 1 | 2011 | 161 | 0.330 |
Why?
|
| Community-Acquired Infections | 1 | 2011 | 241 | 0.310 |
Why?
|
| Staphylococcus aureus | 2 | 2010 | 463 | 0.290 |
Why?
|
| Thymol | 1 | 2007 | 2 | 0.290 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2024 | 2096 | 0.290 |
Why?
|
| Retrospective Studies | 9 | 2024 | 16363 | 0.280 |
Why?
|
| Middle Aged | 12 | 2025 | 26765 | 0.280 |
Why?
|
| Urinary Catheterization | 1 | 2007 | 81 | 0.280 |
Why?
|
| Pneumonia | 1 | 2011 | 325 | 0.280 |
Why?
|
| Equipment Contamination | 2 | 2005 | 37 | 0.270 |
Why?
|
| Chlorhexidine | 5 | 2006 | 47 | 0.260 |
Why?
|
| Drug Delivery Systems | 1 | 2007 | 188 | 0.260 |
Why?
|
| Escherichia coli | 2 | 2010 | 985 | 0.260 |
Why?
|
| Male | 19 | 2025 | 61561 | 0.260 |
Why?
|
| Adenocarcinoma | 1 | 2013 | 1025 | 0.260 |
Why?
|
| Postoperative Complications | 3 | 2025 | 3056 | 0.260 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2013 | 730 | 0.260 |
Why?
|
| Female | 22 | 2025 | 66815 | 0.250 |
Why?
|
| Prosthesis-Related Infections | 3 | 2005 | 176 | 0.240 |
Why?
|
| Glycopeptides | 1 | 2005 | 28 | 0.240 |
Why?
|
| Urinary Tract Infections | 2 | 2007 | 300 | 0.240 |
Why?
|
| Socioeconomic Factors | 4 | 2021 | 860 | 0.240 |
Why?
|
| Predictive Value of Tests | 3 | 2022 | 2182 | 0.230 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2013 | 1272 | 0.210 |
Why?
|
| Vancomycin | 1 | 2005 | 217 | 0.210 |
Why?
|
| Scotland | 3 | 2021 | 17 | 0.200 |
Why?
|
| Staphylococcal Infections | 3 | 2005 | 562 | 0.200 |
Why?
|
| United Kingdom | 2 | 2013 | 190 | 0.200 |
Why?
|
| Prospective Studies | 5 | 2021 | 6142 | 0.190 |
Why?
|
| Logistic Models | 2 | 2018 | 1802 | 0.180 |
Why?
|
| Age Factors | 3 | 2024 | 2818 | 0.180 |
Why?
|
| Sex Factors | 2 | 2016 | 1275 | 0.180 |
Why?
|
| Candida albicans | 4 | 2007 | 76 | 0.170 |
Why?
|
| Survival Analysis | 3 | 2021 | 1495 | 0.170 |
Why?
|
| Morbidity | 1 | 2021 | 248 | 0.170 |
Why?
|
| Time Factors | 4 | 2016 | 6311 | 0.170 |
Why?
|
| Rabbits | 6 | 2007 | 718 | 0.160 |
Why?
|
| Sensitivity and Specificity | 4 | 2022 | 2056 | 0.160 |
Why?
|
| Rectal Neoplasms | 2 | 2024 | 78 | 0.150 |
Why?
|
| Orthopedic Fixation Devices | 1 | 1998 | 4 | 0.150 |
Why?
|
| Emergencies | 2 | 2016 | 172 | 0.140 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2022 | 303 | 0.140 |
Why?
|
| Spain | 1 | 2017 | 60 | 0.140 |
Why?
|
| Administration, Intravenous | 1 | 2018 | 143 | 0.140 |
Why?
|
| Tumor Microenvironment | 1 | 2021 | 565 | 0.140 |
Why?
|
| Watchful Waiting | 1 | 2016 | 69 | 0.130 |
Why?
|
| Body Mass Index | 1 | 2022 | 1563 | 0.130 |
Why?
|
| Treatment Outcome | 6 | 2025 | 12287 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2018 | 1065 | 0.120 |
Why?
|
| Intestinal Obstruction | 1 | 2017 | 94 | 0.120 |
Why?
|
| Pregnancy, Twin | 1 | 2017 | 180 | 0.120 |
Why?
|
| Minocycline | 4 | 2002 | 38 | 0.120 |
Why?
|
| Psychosocial Deprivation | 1 | 2015 | 5 | 0.120 |
Why?
|
| Iron | 1 | 2018 | 277 | 0.120 |
Why?
|
| Rifampin | 4 | 2002 | 131 | 0.120 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2016 | 145 | 0.120 |
Why?
|
| Multivariate Analysis | 1 | 2018 | 1427 | 0.120 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 1362 | 0.120 |
Why?
|
| Colon | 1 | 2017 | 352 | 0.110 |
Why?
|
| Immunologic Factors | 1 | 2016 | 173 | 0.110 |
Why?
|
| Survival Rate | 2 | 2016 | 2050 | 0.110 |
Why?
|
| Feces | 3 | 2022 | 727 | 0.110 |
Why?
|
| Microbial Sensitivity Tests | 5 | 2007 | 798 | 0.110 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2016 | 205 | 0.110 |
Why?
|
| Obesity | 1 | 2025 | 2252 | 0.110 |
Why?
|
| Catheters, Indwelling | 3 | 2007 | 153 | 0.100 |
Why?
|
| Chemoprevention | 1 | 2013 | 58 | 0.100 |
Why?
|
| Respiratory Tract Infections | 1 | 2016 | 274 | 0.100 |
Why?
|
| Pregnancy Complications | 1 | 2017 | 515 | 0.100 |
Why?
|
| Length of Stay | 2 | 2024 | 1310 | 0.100 |
Why?
|
| Databases, Factual | 1 | 2016 | 1172 | 0.090 |
Why?
|
| Risk | 1 | 2013 | 759 | 0.090 |
Why?
|
| Sonication | 1 | 2010 | 8 | 0.090 |
Why?
|
| Adult | 6 | 2024 | 29540 | 0.090 |
Why?
|
| Hemoglobins | 2 | 2022 | 312 | 0.090 |
Why?
|
| Colectomy | 2 | 2024 | 74 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2016 | 1157 | 0.090 |
Why?
|
| Hospitals, Veterans | 2 | 2011 | 357 | 0.080 |
Why?
|
| Aged, 80 and over | 4 | 2024 | 6560 | 0.080 |
Why?
|
| Staphylococcus epidermidis | 2 | 2002 | 39 | 0.080 |
Why?
|
| Follow-Up Studies | 2 | 2016 | 5171 | 0.080 |
Why?
|
| Antibiotics, Antitubercular | 2 | 2002 | 33 | 0.080 |
Why?
|
| Algorithms | 1 | 2016 | 1633 | 0.080 |
Why?
|
| Candidiasis | 2 | 2007 | 129 | 0.070 |
Why?
|
| Risk Assessment | 1 | 2017 | 3431 | 0.070 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2007 | 52 | 0.070 |
Why?
|
| Health Care Costs | 1 | 2011 | 372 | 0.070 |
Why?
|
| Cohort Studies | 2 | 2021 | 4828 | 0.070 |
Why?
|
| Muscle, Skeletal | 2 | 2024 | 945 | 0.070 |
Why?
|
| Evaluation Studies as Topic | 2 | 2005 | 257 | 0.070 |
Why?
|
| Heart Valve Prosthesis | 2 | 2002 | 302 | 0.070 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 1 | 2007 | 70 | 0.070 |
Why?
|
| Bacterial Infections | 2 | 2007 | 307 | 0.060 |
Why?
|
| Antisepsis | 1 | 2006 | 8 | 0.060 |
Why?
|
| Disinfectants | 1 | 2006 | 25 | 0.060 |
Why?
|
| Candida | 1 | 2006 | 75 | 0.060 |
Why?
|
| Antitubercular Agents | 1 | 2007 | 252 | 0.060 |
Why?
|
| Teicoplanin | 1 | 2005 | 4 | 0.060 |
Why?
|
| Bacteria | 1 | 2007 | 481 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 2 | 2016 | 625 | 0.050 |
Why?
|
| Biology | 1 | 2023 | 30 | 0.050 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2007 | 456 | 0.050 |
Why?
|
| Intra-Abdominal Fat | 1 | 2022 | 52 | 0.050 |
Why?
|
| Bacterial Adhesion | 3 | 1998 | 106 | 0.050 |
Why?
|
| Stress, Physiological | 1 | 2024 | 256 | 0.050 |
Why?
|
| Demography | 1 | 2022 | 238 | 0.050 |
Why?
|
| Lymphocyte Count | 1 | 2021 | 118 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2021 | 250 | 0.040 |
Why?
|
| Animals | 7 | 2007 | 34318 | 0.040 |
Why?
|
| Catheterization, Central Venous | 2 | 1998 | 130 | 0.040 |
Why?
|
| Bone Nails | 1 | 1998 | 22 | 0.040 |
Why?
|
| Coated Materials, Biocompatible | 1 | 1998 | 38 | 0.040 |
Why?
|
| Premedication | 1 | 1998 | 41 | 0.040 |
Why?
|
| Laparoscopy | 1 | 2024 | 491 | 0.040 |
Why?
|
| Fracture Fixation, Intramedullary | 1 | 1998 | 19 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2021 | 543 | 0.040 |
Why?
|
| Tibial Fractures | 1 | 1998 | 59 | 0.040 |
Why?
|
| Blood | 1 | 1998 | 104 | 0.040 |
Why?
|
| Abdomen | 1 | 2018 | 127 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2022 | 578 | 0.030 |
Why?
|
| Klebsiella Infections | 1 | 1997 | 54 | 0.030 |
Why?
|
| Conservative Treatment | 1 | 2017 | 36 | 0.030 |
Why?
|
| Klebsiella pneumoniae | 1 | 1997 | 76 | 0.030 |
Why?
|
| Lymphatic Vessels | 1 | 2016 | 37 | 0.030 |
Why?
|
| Pseudomonas aeruginosa | 1 | 1998 | 164 | 0.030 |
Why?
|
| Blood Vessels | 1 | 2016 | 102 | 0.030 |
Why?
|
| Equipment Design | 1 | 1998 | 589 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2016 | 121 | 0.030 |
Why?
|
| Iran | 1 | 2016 | 89 | 0.030 |
Why?
|
| DNA, Bacterial | 1 | 1997 | 475 | 0.030 |
Why?
|
| Consanguinity | 1 | 2016 | 116 | 0.030 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2018 | 138 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2016 | 418 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2016 | 237 | 0.030 |
Why?
|
| Risk Factors | 2 | 2021 | 10296 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2016 | 880 | 0.030 |
Why?
|
| Delayed Diagnosis | 1 | 2016 | 126 | 0.030 |
Why?
|
| Age of Onset | 1 | 2016 | 601 | 0.030 |
Why?
|
| Cesarean Section | 1 | 2017 | 390 | 0.030 |
Why?
|
| Neurotoxins | 1 | 1993 | 56 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2016 | 630 | 0.030 |
Why?
|
| Lymph Nodes | 1 | 2014 | 378 | 0.020 |
Why?
|
| Monocytes | 1 | 1993 | 345 | 0.020 |
Why?
|
| Brain Ischemia | 1 | 1993 | 265 | 0.020 |
Why?
|
| Young Adult | 2 | 2016 | 9058 | 0.020 |
Why?
|
| Pregnancy | 2 | 2017 | 7226 | 0.020 |
Why?
|
| Brain Injuries | 1 | 1993 | 702 | 0.020 |
Why?
|
| Silver Sulfadiazine | 2 | 1998 | 9 | 0.020 |
Why?
|
| Colony Count, Microbial | 2 | 1998 | 88 | 0.020 |
Why?
|
| Drug Therapy, Combination | 2 | 2002 | 1172 | 0.020 |
Why?
|
| Drug Combinations | 2 | 1998 | 265 | 0.020 |
Why?
|
| Catheterization | 1 | 2006 | 227 | 0.010 |
Why?
|
| Adolescent | 2 | 2016 | 19423 | 0.010 |
Why?
|
| Bacillus | 1 | 2002 | 35 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2016 | 14145 | 0.010 |
Why?
|
| Drug Stability | 1 | 1998 | 58 | 0.010 |
Why?
|
| Disease Models, Animal | 2 | 1998 | 4409 | 0.010 |
Why?
|
| Mannose | 1 | 1997 | 25 | 0.010 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 1998 | 150 | 0.010 |
Why?
|
| Fimbriae, Bacterial | 1 | 1997 | 42 | 0.010 |
Why?
|
| Antibiotic Prophylaxis | 1 | 1998 | 118 | 0.010 |
Why?
|
| Random Allocation | 1 | 1998 | 439 | 0.010 |
Why?
|
| DNA Fingerprinting | 1 | 1997 | 108 | 0.010 |
Why?
|
| Antibodies, Blocking | 1 | 1997 | 62 | 0.010 |
Why?
|
| Half-Life | 1 | 1996 | 159 | 0.010 |
Why?
|
| Gram-Positive Bacteria | 1 | 1996 | 47 | 0.010 |
Why?
|
| Gram-Negative Bacteria | 1 | 1996 | 68 | 0.010 |
Why?
|
| Prosthesis Design | 1 | 1998 | 668 | 0.010 |
Why?
|
| Child | 1 | 2016 | 24606 | 0.010 |
Why?
|
| Cross Infection | 1 | 1997 | 325 | 0.010 |
Why?
|
| Spinal Cord Injuries | 1 | 1997 | 313 | 0.010 |
Why?
|
| Ganglia, Parasympathetic | 1 | 1993 | 1 | 0.010 |
Why?
|
| Chromatography, Ion Exchange | 1 | 1993 | 66 | 0.010 |
Why?
|
| Culture Media, Conditioned | 1 | 1993 | 82 | 0.010 |
Why?
|
| Recurrence | 1 | 1997 | 1394 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1997 | 1592 | 0.010 |
Why?
|
| Chick Embryo | 1 | 1993 | 131 | 0.010 |
Why?
|
| Microglia | 1 | 1993 | 102 | 0.010 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 1993 | 148 | 0.010 |
Why?
|
| Infant | 1 | 2007 | 12601 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1997 | 3044 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 1993 | 645 | 0.010 |
Why?
|
| Texas | 1 | 1998 | 3581 | 0.000 |
Why?
|